G1 THERAPEUTICS (NASDAQ:GTHX) – Wedbush upped their Q4 2017 earnings per share (EPS) estimates for G1 THERAPEUTICS in a research report issued on Wednesday. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.58) per share for the quarter, up from their previous forecast of ($0.61). Wedbush also issued estimates for G1 THERAPEUTICS’s Q1 2018 earnings at ($0.50) EPS, Q2 2018 earnings at ($0.53) EPS, Q3 2018 earnings at ($0.56) EPS, Q4 2018 earnings at ($0.59) EPS, FY2018 earnings at ($2.18) EPS, FY2019 earnings at ($2.34) EPS, FY2020 earnings at ($2.10) EPS and FY2021 earnings at ($1.31) EPS.
Several other analysts have also weighed in on GTHX. Cowen and Company reissued a “buy” rating on shares of G1 THERAPEUTICS in a report on Wednesday, August 9th. Zacks Investment Research lowered G1 THERAPEUTICS from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $29.75.
Institutional investors have recently bought and sold shares of the stock. American International Group Inc. bought a new position in shares of G1 THERAPEUTICS during the 3rd quarter worth approximately $130,000. California State Teachers Retirement System bought a new position in shares of G1 THERAPEUTICS during the 3rd quarter worth approximately $319,000. Schwab Charles Investment Management Inc. bought a new position in shares of G1 THERAPEUTICS during the 3rd quarter worth approximately $364,000. Alps Advisors Inc. bought a new position in shares of G1 THERAPEUTICS during the 2nd quarter worth approximately $444,000. Finally, Bank of New York Mellon Corp bought a new position in shares of G1 THERAPEUTICS during the 3rd quarter worth approximately $568,000. Institutional investors and hedge funds own 35.28% of the company’s stock.
About G1 THERAPEUTICS
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.